ABT — Abbott Laboratories Cashflow Statement
0.000.00%
Last trade - 00:00- $183.26bn
- $187.89bn
- $44.33bn
Annual cashflow statement for Abbott Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 695 | 900 | 770 | 1,155 | 729 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -771 | -1,519 | -2,475 | -9,217 | -803 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | 10,533 | 9,581 | 7,261 | 8,558 | 9,566 |
| Capital Expenditures | -1,885 | -1,777 | -2,202 | -2,207 | -2,171 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -123 | 37 | -931 | -131 | -251 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2,008 | -1,740 | -3,133 | -2,338 | -2,422 |
| Financing Cash Flow Items | 0 | — | — | — | -82 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -5,494 | -7,636 | -7,091 | -5,404 | -6,309 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2,961 | 83 | -2,986 | 720 | 906 |